A real-world study of millions of Chileans who had received the Chinese-developed CoronaVac vaccine has found it 67% effective against symptoms and 80% against death from COVID-19, the South American country's Health Ministry said Friday.
Ministry adviser Rafael Araos said the study covered 10.5 million people, including 2.5 million who had received both doses of the vaccine and 1.5 million who had received a single dose between Feb. 2 and April 1.
It counted cases starting 14 days after application of the second dose of the vaccine, which in Chile was given 28 days after the first.
The vaccine has been widely used across the world, though not in the United States or Europe.
Araos said it had reduced hospitalizations by 85%, intensive care visits by 89% and deaths by 80%.
Read the full article here.
Refana Inc., is United States registered private corporation dedicated to finding practical and innovative solutions to the world's medical problems. By utilizing a highly collaborative open source system of research and development Refana has been able to attract world leaders in their respective scientific and medical fields to work on these problems. Through this model Refana hopes to greatly accelerate the vaccine development process for Covid-19 and help protect not only the health of the world, but also the economies and stability of nations at risk.